Business Wire

The Interfaith Alliance for Safer Communities Hosted A Roundtable Event - Covid-19: Faith as a Moral Framework for our Communities

7.9.2020 16:00:00 EEST | Business Wire | Press release

Share

The Interfaith Alliance for Safer Communities (IAFSC), an NGO established to empower faith leaders to work for the safety and security of communities, has held a successful online interfaith roundtable event with representation from 50 participants representing 7 faiths from 18 countries.

Speaking about the event, Dr. Vinu Aram (Director of Shanti Ashram and Co-Moderator of Religions for Peace) said, “I want to thank the Interfaith Alliance for Safer Communities for this meeting today. The work of the Interfaith Alliance is so important: in the disruption of the ways we worked together as communities during Covid-19, we have found that children have become more vulnerable... While every nation is trying to find its own solution, those of us who work with children have to be greater advocates for their cause.”

Chief Executive of the IAFSC, Dana Humaid, said “Faith has rarely been more important or powerful than in the current crisis. The IAFSC hosted this event in order to allow discussion and facilitate knowledge-sharing from different religions and communities on a global scale. Faith leaders have the power to assist their communities, to be advocates for those in need, to make a difference and offer comfort and also to try and reduce the suffering of people under their watch.”

The ongoing Covid-19 pandemic has been unprecedented in modern times, and has had a significant impact on the physical, mental and spiritual wellbeing of our communities. Millions have lost their jobs and are facing struggles such as hunger and homelessness. This pandemic has had unforeseen consequences as well, such as a surge in the cases of child sexual abuse as well as an increase in hate crimes based on race and religion.

Key Outcomes

The roundtable discussions aimed to address the most significant problems being faced by our communities today.

Supporting those most impacted by coronavirus in rebuilding their lives

  • We are all impacted by this pandemic, we are not all affected the same way.
  • The role of faith and faith leaders is to build, promote and invigorate a spirit of resilience.
  • When faith leaders aren’t able to contact their community and provide them with help or assistance in a difficult time, it is a challenge for everyone in the community.
  • Faith leaders have been taking on the bulk of the work in some communities.
  • We need to be careful of our blind spots, we cannot create a situation in which we overlook other communities that now need our help, such as those that may not be considered traditionally vulnerable sectors of society.

Protecting the digital dignity of children and supporting the victims and their families

  • Faith leaders can be champions in leading the prevention of sexual exploitation.
  • It is important to base our responses on data and evidence and go from there.
  • No one is an expert in the prevention of exploitation. Community is key.
  • We need to increase budgets for social and health services.
  • Family and family stability are also vital.
  • Education, mobilization, support and universal healthcare are all necessary in improving our communities.

Among others, organisations represented included: Arigatou International, ECPAT International, New York Board of Rabbis, Conference of European Rabbis, Bahá'í International Community, Peres Center for Peace and Innovation, Shanti Ashram, World Economic Forum, UNICEF, Conference of European Churches, Markaz Knowledge City (India), and Online Anti-Semitism Task Force.

Visit https://iafsc.org/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information:
Caroline Sullivan
media@iasfc.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye